Scarica l'app Stockscreener
15.70
6.72%
0.97
Precedente Chiudi:
$14.73
Aprire:
$15.06
Volume 24 ore:
249.55K
Relative Volume:
0.08
Capitalizzazione di mercato:
$980.46M
Reddito:
$16.10M
Utile/perdita netta:
$-198.97M
Rapporto P/E:
-4.5103
EPS:
-3.4809
Flusso di cassa netto:
$-183.99M
1 W Prestazione:
+3.56%
1M Prestazione:
+0.58%
6M Prestazione:
-73.07%
1 anno Prestazione:
+48.30%
Intervallo 1D:
$15.04
$15.90
Intervallo di 1 settimana:
$14.51
$16.96
Portata 52W:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
15.68 | 921.06M | 16.10M | -198.97M | -183.99M | -3.4809 |
VRTX
Vertex Pharmaceuticals Inc
|
444.71 | 112.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
771.22 | 79.21B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
714.62 | 43.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.19 | 41.92B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
161.01 | 33.05B | 606.42M | -1.28B | -997.58M | -6.403 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2026-03-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors - globenewswire.com
Contact Levi & Korsinsky by April 13, 2026 Deadline to Join Class Action Against uniQure N.V. (QURE) - globenewswire.com
QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm - globenewswire.com
March 2026: Pharmacological advancements in rare diseases - The Pharma Letter
uniQure N.V. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsQURE - ChartMill
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - PR Newswire
Rosen Law Firm Encourages uniQure Investors to Secure Counsel Before Deadline - National Today
ROSEN Firm Encourages uniQure Investors to Secure Counsel - National Today
ROSEN, A TRUSTED AND LEADING INVESTOR RIGHTS FIRM, Encourages uniQure N.V. Investors to Secure ... - Caledonian Record
ROSEN, A TRUSTED AND LEADING INVESTOR RIGHTS FIRM, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
uniQure N.V. (QURE): A Bull Case Theory - MSN
UniQure surges following departure of key FDA official - MSN
UniQure NV (NASDAQ:QURE) Q4 2025 earnings call transcript - msn.com
uniQure (NASDAQ:QURE) Raised to Hold at Wall Street Zen - MarketBeat
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - PR Newswire
UniQure NV (QURE) price target decreased by 26.57% to 37.82 - MSN
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit - ChartMill
QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data - GlobeNewswire Inc.
QURE Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - marketscreener.com
uniQure NV (FRA:UQ1) PE Ratio : At Loss (As of Mar. 27, 2026) - GuruFocus
uniQure NV (FRA:UQ1) NonCurrent Deferred Revenue : €0.00 Mil (As of Dec. 2025) - GuruFocus
Assenagon Asset Management S.A. Makes New Investment in uniQure N.V. $QURE - MarketBeat
NASDAQ: QURE: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against uniQure N.V. - NewMediaWire
QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data - ChartMill
QURE Shareholders Have Opportunity to Lead uniQure N.V. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
User - The Chronicle-Journal
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming DeadlinesQURE - PR Newswire
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - globenewswire.com
QURE stock crashes 32% in a week: Here's what you should know - MSN
QURE DEADLINE NOTICE: uniQure N.V. Investors Encouraged to Contact Kirby McInerney LLP By April 13, 2026 - ACCESS Newswire
uniQure Shareholder Alert: ClaimsFiler Reminds Investors - globenewswire.com
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V.QURE - ChartMill
QURE ALERT: Hagens Berman Updates uniQure (QURE) - GlobeNewswire
QURE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - marketscreener.com
Levi & Korsinsky Reminds uniQure N.V. Investors of the Pending C - GuruFocus
Levi & Korsinsky Reminds uniQure N.V. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 13, 2026QURE - PR Newswire
Chardan Capital maintains uniQure NV (QURE) buy recommendation - MSN
QURE Shareholder Alert: uniQure N.V. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - Sahm
uniQure Faces Securities Fraud Lawsuit After FDA Approval Delay - nationaltoday.com
Gartner, Inc. Securities Fraud Class Action Result of Reduced Guidance Disclosure and 48% Stock Decline - GlobeNewswire Inc.
Driven Brands Holdings Inc. Securities Fraud Class Action Result of Erroneous Financial Statements and 39% Stock Decline - GlobeNewswire Inc.
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - GlobeNewswire Inc.
uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed; April 13, 2026, Lead Plaintiff Deadline - ChartMill
Liquidity Mapping Around (QURE) Price Events - Stock Traders Daily
uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims - TipRanks
UNIQURE N.V. (QURE) Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action - marketscreener.com
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Holzer & Holzer, LLC Reminds Investors of April 13, 2026 - GlobeNewswire
Barclays Maintains uniQure (QURE) Rating, Lowers Price Target | QURE Stock News - GuruFocus
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Uniqure N V Azioni (QURE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | Chief Medical Officer |
Mar 04 '26 |
Sale |
9.06 |
808 |
7,320 |
189,669 |
| Potts Jeannette | Chief Legal Officer |
Mar 04 '26 |
Sale |
9.06 |
3,412 |
30,913 |
138,483 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Mar 04 '26 |
Sale |
9.06 |
12,000 |
108,720 |
226,581 |
0.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):